Ardelyx, Inc.
ARDX
ARDX: Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
moreShow ARDX Financials
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of ARDX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ARDX's directors and management
Government lobbying spending instances
-
$310,000 Jul 17, 2023 Issue: Medicare/Medicaid
-
$240,000 Apr 17, 2023 Issue: Medicare/Medicaid
-
$130,000 Jan 17, 2023 Issue: None
-
$130,000 Jan 05, 2023 Issue: None
-
$50,000 Oct 20, 2022 Issue: Health Issues
-
$30,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$130,000 Jul 22, 2022 Issue: None
-
$130,000 Apr 20, 2022 Issue: None
-
$260,000 Jan 20, 2022 Issue: None
-
$240,000 Oct 20, 2021 Issue: None
-
$220,000 Jul 19, 2021 Issue: None
-
$190,000 Apr 19, 2021 Issue: None
-
$170,000 Jan 21, 2021 Issue: None
-
$30,000 Oct 20, 2020 Issue: Medicare/Medicaid
-
$30,000 Jul 20, 2020 Issue: Medicare/Medicaid
-
$30,000 Apr 21, 2020 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: Medicare/Medicaid
-
$30,000 Oct 18, 2019 Issue: Medicare/Medicaid
-
$30,000 Jul 12, 2019 Issue: Medicare/Medicaid
-
$30,000 Apr 04, 2019 Issue: Medicare/Medicaid
-
$10,000 Jan 09, 2019 Issue: Medicare/Medicaid Health Issues
U.S. Patents
New patents grants
-
Patent Title: Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators Aug. 08, 2023
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders May. 03, 2022
-
Patent Title: Compounds useful for treating gastrointestinal tract disorders Feb. 08, 2022
-
Patent Title: Inhibitors of nhe-mediated antiport Oct. 19, 2021
-
Patent Title: Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators Aug. 17, 2021
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Apr. 06, 2021
-
Patent Title: Nhe3-binding compounds and methods for inhibiting phosphate transport Mar. 09, 2021
-
Patent Title: Hormone receptor modulators for treating metabolic conditions and disorders Oct. 06, 2020
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Jan. 28, 2020
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Aug. 27, 2019
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug. 20, 2019
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug. 13, 2019
-
Patent Title: Nhe3-binding compounds and methods for inhibiting phosphate transport Apr. 30, 2019
-
Patent Title: Compositions and methods for treating hyperkalemia Mar. 20, 2018
-
Patent Title: Compositions and methods for treating hyperkalemia Jan. 16, 2018
-
Patent Title: Compositions and methods for treating hyperkalemia May. 23, 2017
-
Patent Title: Pharmaceutical compositions for treating hyperkalemia Jan. 24, 2017
-
Patent Title: Pharmaceutical compositions for treating hyperkalemia Jan. 17, 2017
-
Patent Title: Compositions and methods for treating hyperkalemia Sep. 06, 2016
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder Aug. 09, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Apr. 05, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 22, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 22, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 08, 2016
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Apr. 14, 2015
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Mar. 03, 2015
-
Patent Title: Compounds and methods for inhibiting phosphate transport Dec. 23, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 26, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 26, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 19, 2014
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Sep. 24, 2013
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on ARDX's company Twitter account
WallStreetBets
Number of mentions of ARDX in WallStreetBets Daily Discussion
ARDX News
Recent insights relating to ARDX
CNBC Recommendations
Recent picks made for ARDX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ARDX
Corporate Flights
Flights by private jets registered to ARDX